Guardant Health, Inc. $GH Position Increased by Legal & General Group Plc

Legal & General Group Plc increased its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 3.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 156,779 shares of the company’s stock after acquiring an additional 5,174 shares during the period. Legal & General Group Plc owned about 0.12% of Guardant Health worth $16,013,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of GH. V Square Quantitative Management LLC purchased a new stake in shares of Guardant Health during the fourth quarter worth $27,000. Chesapeake Asset Management LLC bought a new position in Guardant Health during the fourth quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Guardant Health during the fourth quarter valued at about $31,000. Elyxium Wealth LLC bought a new position in Guardant Health during the fourth quarter valued at about $35,000. Finally, First Pacific Financial bought a new position in Guardant Health during the fourth quarter valued at about $43,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider John G. Saia sold 20,000 shares of Guardant Health stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $106.51, for a total transaction of $2,130,200.00. Following the sale, the insider directly owned 45,950 shares of the company’s stock, valued at $4,894,134.50. This trade represents a 30.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Chris Freeman sold 24,406 shares of Guardant Health stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $118.67, for a total value of $2,896,260.02. Following the sale, the insider directly owned 60,034 shares in the company, valued at approximately $7,124,234.78. This trade represents a 28.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 332,244 shares of company stock valued at $36,156,026 in the last ninety days. Company insiders own 5.60% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on GH. BTIG Research set a $160.00 target price on Guardant Health and gave the company a “buy” rating in a report on Wednesday, May 27th. Evercore set a $110.00 target price on Guardant Health in a report on Friday, February 20th. Citigroup raised their target price on Guardant Health from $135.00 to $150.00 and gave the company a “buy” rating in a report on Friday, February 20th. Stifel Nicolaus raised their target price on Guardant Health from $120.00 to $130.00 and gave the company a “buy” rating in a report on Friday, February 20th. Finally, TD Cowen restated a “buy” rating on shares of Guardant Health in a report on Thursday, May 21st. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $129.79.

Guardant Health Stock Performance

Guardant Health stock opened at $129.14 on Tuesday. The business’s 50-day simple moving average is $95.88 and its 200-day simple moving average is $100.18. The firm has a market capitalization of $17.12 billion, a PE ratio of -38.09 and a beta of 1.48. Guardant Health, Inc. has a 52 week low of $39.69 and a 52 week high of $133.97.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.